

Inhaler Guidance in pictures

SABA = short-acting β 2-agonist; LABA = long-acting β 2-agonist; ICS = inhaled corticosteroid; LAMA = long-acting muscarinic antagonist; LTRA=leukotriene receptor antagonist

<u>ASTHMA</u>

1 st choice	2 nd choice
Salbutamol MDI	Easyhaler® Salbutamol
100micrograms	100micrograms
One or two inhalations as	One or two inhalations
required	as required
200 doses £1.46	200 doses £3.31

Regular preventer therapy with low dose ICS

1 st choice		
Soprobec® 100 micrograms MDI (beclometasone dipropionate)	OR	Easyhaler® Beclometasone 200 microgram
Two inhalations twice daily £3.34		One inhalation twice daily £4.48


Reference: Version 1.0Supersedes: NonePage 1 of 8Written by: C Kerr (Lead Pharmacist) & A Foster (Senior Pharmacist) on behalf of the Respiratory MCNDate prepared: March 2021Review date: August 2023

SABA



<u>Asthma</u>

Initial add on therapy: add inhaled LABA to low dose ICS (as combination inhaler)



** Both Fostair® 100/6 and Fobumix® Easyhaler® 160/4.5 can be used as Maintenance and Reliever Therapy (MART)

<u>Asthma</u>

Additional controller therapies

• No response to LABA - stop LABA and consider increased dose of ICS to medium dose or initiate a trial of LTRA.

• Response to LABA but control remains suboptimal recheck the diagnosis, assess adherence to existing medication and check inhaler technique before increasing therapy. If more intensive treatment is appropriate then consider the following:

– continue LABA and increase ICS to medium dose (1st choice Airflusal® 125/25 MDI or Fobumix® Easyhaler® 160/4.5)

OR


continue LABA & ICS and consider trial of other therapy – LTRA (montelukast 10mg tablets one each evening, LAMA (Spiriva® Respimat ® 2.5 micrograms – Two inhalations once daily) or SR theophylline (Uniphyllin®)

Ensure each is given on a trial basis if no response discontinue and reassess.

1 st choice		
Airflusal® 125/25 MDI (fluticasone/salmeterol)	OR	Fobumix® Easyhaler® 160/4.5 (budesonide/formoterol)
Two inhalations twice daily £16.42		Two inhalations twice daily £21.50



2 nd choice		
Fostair® 100/6 MDI (beclometasone/formoterol)	OR	Relvar® Ellipta® 92/22 (fluticasone /vilanterol)*
Two inhalations twice daily £29.32		One inhalation once daily £22.00



<u>Asthma</u>

Specialist therapies

All patients whose asthma is not adequately controlled on recommended initial or additional controller therapies should be referred for specialist care. If asthma control remains inadequate on medium dose ICS and LABA or LTRA the following can be considered increasing ICS to high dose / addition of 4th drug e.g. LTRA, (montelukast 10mg tablets one each evening, LAMA (Spiriva® Respimat ® 2.5 micrograms – Two inhalations once daily) or SR theophylline (Uniphyllin®)

1 st choice		
Airflusal® 250/25 MDI (fluticasone/salmeterol)	OR	Fobumix® Easyhaler® 320/9 (budesonide/formoterol)
Two inhalations twice daily £20.52		One - Two inhalations twice daily £21.50- £43.00

2 nd choice		
Fostair® 200/6 MDI (beclometasone/formoterol)	OR	Relvar® Ellipta® 184/22 (fluticasone /vilanterol)*
Two inhalations twice daily with spacer £29.32		One inhalation once daily £29.50

Continuous or frequent use of oral corticosteroids - Refer for specialist care

<u>COPD</u>


SABA

1 st choice	2 nd choice
Salbutamol MDI	Easyhaler® Salbutamol
100micrograms	100micrograms
One or two inhalations as	One or two inhalations
required	as required
200 doses £1.46	200 doses £3.31

LABA

1 st choice		
Atimos Modulite® MDI 12 micrograms MDI (formoterol)	Formoterol Easyhaler® 12 micrograms	
One to two inhalations twice daily £18.04 – 36.08	One to two inhalations twice daily £11.87 – 23.75	

LAMA




ICS/LABA


1 st choice		
Relvar® Ellipta® 92/22 (fluticasone/vilanterol)*		Fostair® 100/6 MDI (beclometasone/formoterol)
One inhalation once daily £22.00	OR	Two inhalations twice daily £29.32

<u>COPD</u>

LAMA/LABA



(ICS/LABA/LAMA)



*Permissions were obtained from individual companies to reproduce pictures January 2021 NHS Ayrshire and Arran COPD and Asthma Guidelines were updated August 2020